share_log

Evercore ISI Group Maintains Outperform on Travere Therapeutics, Lowers Price Target to $14

Benzinga ·  Sep 22, 2023 11:17

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and lowers the price target from $30 to $14.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment